Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial

BMC Complementary and Alternative Medicine

Alan L Hinderliter²  Melissa Caughey²  Rosalie Dominik⁴  Mark A Weaver¹  Anthony J Viera³  Gary N Asher³ 

[1] Department of Medicine, University of North Carolina, Chapel Hill, NC, USA;Division of Cardiology, University of North Carolina, Chapel Hill, NC, USA;Department of Family Medicine, University of North Carolina, Chapel Hill, NC, USA;Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA

关键词: Phase I;    flow mediated dilation;    prehypertension;    hypertension;    Crataegus;    Hawthorn;   

Others  :  1232783
DOI  :  10.1186/1472-6882-12-26

 received in 2011-12-20, accepted in 2012-03-29,  发布年份 2012

【 摘 要 】

Background

Hawthorn extract has been used for cardiovascular diseases for centuries. Recent trials have demonstrated its efficacy for the treatment of heart failure, and the results of several small trials suggest it may lower blood pressure. However, there is little published evidence to guide its dosing. The blood pressure lowering effect of hawthorn has been linked to nitric oxide-mediated vasodilation. The aim of this study was to investigate the relationship between hawthorn extract dose and brachial artery flow mediated dilation (FMD), an indirect measure of nitric oxide release.

Methods

We used a four-period cross-over design to evaluate brachial artery FMD in response to placebo or hawthorn extract (standardized to 50 mg oligomeric procyanidin per 250 mg extract). Randomly sequenced doses of hawthorn extract (1000 mg, 1500 mg, and 2500 mg) and placebo were assigned to each participant. Doses were taken twice daily for 3 1/2 days followed by FMD and a 4-day washout before proceeding to the next dosing period.

Results

Twenty-one prehypertensive or mildly hypertensive adults completed the study. There was no evidence of a dose-response effect for our main outcome (FMD percent) or any of our secondary outcomes (absolute change in brachial artery diameter and blood pressure). Most participants indicated that if given evidence that hawthorn could lower their blood pressure, they would be likely to use it either in conjunction with or instead of lifestyle modification or anti-hypertensive medications.

Conclusion

We found no evidence of a dose-response effect of hawthorn extract on FMD. If hawthorn has a blood pressure lowering effect, it is likely to be mediated via an NO-independent mechanism.

Trial Registration

This trial has been registered with ClinicalTrials.gov, a service of the U.S. National Institutes of Health: NCT01331486.

【 授权许可】

   
2012 Asher et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Upton R (Ed): Hawthorn Berry In American Herbal Pharmacopoeia. Scotts Valley: AHP; 1999:24.
• [2]Chang Q, Zuo Z, Harrison F, Chow MS: Hawthorn. J Clin Pharmacol 2002, 42(6):605-612.
• [3]Brixius K, Willms S, Napp A, Tossios P, Ladage D, Bloch W, Mehlhorn U, Schwinger RH: Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177. Cardiovasc Drugs Ther 2006, 20(3):177-184.
• [4]Kim SH, Kang KW, Kim KW, Kim ND: Procyanidins in crataegus extract evoke endothelium-dependent vasorelaxation in rat aorta. Life Sci 2000, 67(2):121-131.
• [5]Koch E, Chatterjee S: Crataegus extract WS 1442 enhances coronary flow in the isolated rat heart by endothelial release of nitric oxide. Naunyn Schmiedebergs Arch Pharmacol 2000, 361(Suppl):R48.
• [6]Ellingwood F: JU L: American Materia Medica, Therapeutics and Pharmacognosy. Evanston: Ellingwood's Therapeutist; 1915.
• [7]ESCOP Monographs 2nd edition. Stuttgart: Thieme; 2003.
• [8]Guo R, Pittler MH, Ernst E: Hawthorn extract for treating chronic heart failure. Cochrane Database Syst Rev 2008, (1):CD005312.
• [9]Asgary S, Naderi GH, Sadeghi M, Kelishadi R, Amiri M: Antihypertensive effect of Iranian Crataegus curvisepala Lind.: a randomized, double-blind study. Drugs Exp Clin Res 2004, 30(5-6):221-225.
• [10]Walker AF, Marakis G, Morris AP, Robinson PA: Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mild, essential hypertension. Phytother Res 2002, 16(1):48-54.
• [11]Walker AF, Marakis G, Simpson E, Hope JL, Robinson PA, Hassanein M, Simpson HC: Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract 2006, 56(527):437-443.
• [12]Chen JD, Wu YZ, Tao ZL, Chen ZM, Liu XP: Hawthorn (shan zha) drink and its lowering effect on blood lipid levels in humans and rats. World Rev Nutr Diet 1995, 77:147-154.
• [13]Rajendran S, Deepalakshmi PD, Parasakthy K, Devaraj H, Devaraj SN: Effect of tincture of Crataegus on the LDL-receptor activity of hepatic plasma membrane of rats fed an atherogenic diet. Atherosclerosis 1996, 123(1-2):235-241.
• [14]Shanthi S, Parasakthy K, Deepalakshmi PD, Devaraj SN: Hypolipidemic activity of tincture of Crataegus in rats. Indian J Biochem Biophys 1994, 31(2):143-146.
• [15]Shanthi S, Parasakthy K, Deepalakshmi PD, Niranjjali D: Protective effect of tincture of Crataegus on wxidative stress in experimental atherosclerosis in rats. J Clin Biochem Nutr 1996, 20:211-223.
• [16]Zhang Z, Ho WK, Huang Y, James AE, Lam LW, Chen ZY: Hawthorn fruit is hypolipidemic in rabbits fed a high cholesterol diet. J Nutr 2002, 132(1):5-10.
• [17]Moens AL, Goovaerts I, Claeys MJ, Vrints CJ: Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 2005, 127(6):2254-2263.
• [18]Tauchert M: Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002, 143(5):910-915.
• [19]Tauchert M, Gildor A, Lipinski J: [High-dose Crataegus extract WS 1442 in the treatment of NYHA stage II heart failure]. Herz 1999, 24(6):465-474. discussion 475
• [20]Weikl A, Assmus KD, Neukum-Schmidt A, Schmitz J, Zapfe G, Noh HS, Siegrist J: [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)]. Fortschr Med 1996, 114(24):291-296.
• [21]Chang Q, Zuo Z, Ho WK, Chow MS: Comparison of the pharmacokinetics of hawthorn phenolics in extract versus individual pure compound. J Clin Pharmacol 2005, 45(1):106-112.
• [22]Wang B, Wang X, Gong L: The Construction of a Williams Design and Randomization in Cross-Over Clinical Trials Using SAS. Journal of Statistical Software 2009., 29Code snippet 1, pp1-10
• [23]Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39(2):257-265.
• [24]Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ: Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005, 45(1):142-161.
• [25]Dmitrienko A, Fritsch K, Hsu J, Ruberg S: Design and analysis of dose-ranging clinical studies. In Pharmaceutical Statistics Using SAS: A Practical Guide. Edited by Dmitrienko A, Chuangstein C, Ralph D'Agostino S. Cary: SAS Institute, Inc; 2007:274-311.
• [26]Donald AE, Halcox JP, Charakida M, Storry C, Wallace SM, Cole TJ, Friberg P, Deanfield JE: Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation. J Am Coll Cardiol 2008, 51(20):1959-1964.
• [27]Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990, 323(1):22-27.
• [28]Shimbo D, Grahame-Clarke C, Miyake Y, Rodriguez C, Sciacca R, Di Tullio M, Boden-Albala B, Sacco R, Homma S: The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 2007, 192(1):197-203.
• [29]Chen ZY, Zhang ZS, Kwan KY, Zhu M, Ho WK, Huang Y: Endothelium-dependent relaxation induced by hawthorn extract in rat mesenteric artery. Life Sci 1998, 63(22):1983-1991.
• [30]Vierling W, Brand N, Gaedcke F, Sensch KH, Schneider E, Scholz M: Investigation of the pharmaceutical and pharmacological equivalence of different Hawthorn extracts. Phytomedicine 2003, 10(1):8-16.
• [31]Egashira K, Inou T, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Kuga T, Urabe Y, Takeshita A: Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation 1993, 88(1):77-81.
• [32]Gerhard M, Roddy MA, Creager SJ, Creager MA: Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996, 27(4):849-853.
• [33]Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, Salvetti A: Age-related reduction of NO availability and oxidative stress in humans. Hypertension 2001, 38(2):274-279.
• [34]Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, Forman S, Ernst KV, Kelemen MD, Townsend SN, Capriotti A, et al.: L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006, 295(1):58-64.
• [35]Zand J, Lanza F, Garg HK, Bryan NS: All-natural nitrite and nitrate containing dietary supplement promotes nitric oxide production and reduces triglycerides in humans. Nutr Res 2011, 31(4):262-269.
• [36]Feelisch M, Fernandez BO, Bryan NS, Garcia-Saura MF, Bauer S, Whitlock DR, Ford PC, Janero DR, Rodriguez J, Ashrafian H: Tissue processing of nitrite in hypoxia: an intricate interplay of nitric oxide-generating and -scavenging systems. J Biol Chem 2008, 283(49):33927-33934.
• [37]Blumenthal M, Goldberg A, Brinckmann J: Herbal Medicine: Expanded Commission E Monographs. Newton, MA: IntegrativMedicine; 2000.